Filtered By:
Source: Frontiers in Pharmacology
Infectious Disease: Hepatitis

This page shows you your search results in order of date.

Order by Relevance | Date

Total 3 results found since Jan 2013.

Preparation and optimization of surface stabilized cryptotanshinone nanocrystals with enhanced bioavailability
In conclusion, the results of this study suggest a feasible formulation for the oral delivery of CTS.
Source: Frontiers in Pharmacology - February 3, 2023 Category: Drugs & Pharmacology Source Type: research

Exploring the potential mechanism of Fritiliariae Irrhosae Bulbus on ischemic stroke based on network pharmacology and experimental validation
Conclusion: Based on network pharmacology, the effect of FIB in the treatment of ischemic strokes was discussed through the multi-component-multi-target-multi-pathway. The therapeutic effect and potential mechanisms of FIB on ischemic strokes were preliminarily explored, which provided a ground work for further researches on the pharmacodynamic material basis, mechanism of action and clinical application.
Source: Frontiers in Pharmacology - November 17, 2022 Category: Drugs & Pharmacology Source Type: research

Impact of DAA Treatment on Cardiovascular Disease Risk in Chronic HCV Infection: An Update
Hepatitis C virus (HCV) infection is a systemic disease associated with multiple significant extrahepatic manifestations. Emerging studies indicate association between the HCV infection and a higher incidence of major adverse cardiovascular events such as: coronary artery disease, heart failure, stroke and peripheral artery disease, when compared to general population. Atherosclerosis is a common pathophysiologic mechanism of cardiovascular disease (CVD) development which is the leading cause of mortality in the Western world. Proposed mechanisms of HCV-induced atherosclerosis includes systemic inflammation due to the chro...
Source: Frontiers in Pharmacology - May 11, 2021 Category: Drugs & Pharmacology Source Type: research